The bispecific antibody market is gaining momentum as pharmaceutical and biotechnology companies explore innovative treatments for cancer, autoimmune conditions, and other complex diseases. Unlike conventional monoclonal antibodies, bispecific antibodies can bind two distinct antigens simultaneously, enabling targeted therapeutic mechanisms and potentially improving treatment outcomes. Growing clinical research, advancements in antibody engineering, and increasing regulatory approvals are further supporting the development of these therapies.
DelveInsight’s Bispecific Antibody Competitive Landscape Report provides global insights into marketed therapies, clinical-stage candidates, leading developers, and emerging opportunities across the competitive landscape - https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Bispecific Antibody Pipeline: Key Takeaways
More than 180 companies are evaluating over 250 bispecific antibody candidates across different stages of development. Their progress reflects growing interest in dual-targeting approaches designed to address unmet medical needs and improve existing treatment strategies.
Key developers include Instil Bio, Akeso Biopharma, Janssen, Amgen, Zymeworks, Roche, IGM Biosciences, MacroGenics, Regeneron Pharmaceuticals, Boehringer Ingelheim, ABL Bio, Compass Therapeutics, EpimAb Biotherapeutics, Betta Pharmaceuticals, Affimed Therapeutics, Novo Nordisk, and others.
Prominent pipeline candidates include AXN-2510, AK-104, amivantamab, blinatumomab, ivonescimab, zanidatamab, glofitamab, imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, ABL 102, ZW171, CTX-8371, EMB-01, MCLA-129, AFM13, and Mim8.
Request a sample and explore recent developments in the bispecific antibody market through the Bispecific Antibody Competitive Landscape Report - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Understanding Bispecific Antibodies and Their Applications
Bispecific antibodies are engineered molecules capable of binding two different antigens or epitopes. In oncology, certain candidates bind CD3 on T cells and a tumor-associated antigen, such as CD19, CD20, CD33, CD123, HER2, EpCAM, BCMA, or CEA. This interaction brings immune cells into proximity with cancer cells, helping activate immune responses against malignant cells.
Their applications extend beyond oncology. Emicizumab, also known as ACE910, bridges coagulation factors IXa and X to support blood coagulation in people with hemophilia A. Other candidates are being investigated for osteoporosis, neurological disorders, and inflammatory diseases.
In autoimmune conditions, bispecific antibodies may simultaneously inhibit two inflammatory targets. ABT122, which targets TNF-alpha and IL-17A, has demonstrated clinical activity in rheumatoid and psoriatic arthritis. Conversely, COVA322, another candidate targeting these pathways, was discontinued during early clinical development because of safety concerns. ABT981, which targets IL-1 alpha and IL-1 beta, has been investigated for osteoarthritis.
Potential advantages include improved target specificity, immune-cell recruitment, simultaneous inhibition of disease-related pathways, and reduced reliance on combinations of separate antibody therapies. However, clinical benefits depend on the specific molecule, indication, safety profile, and supporting trial evidence.
Approved Bispecific Antibody Drugs
- Amivantamab: Janssen
Amivantamab is a fully human bispecific antibody targeting EGFR and MET, proteins involved in cancer growth and progression. Developed through a collaboration involving Genmab and Janssen, it uses Genmab’s DuoBody technology platform. In 2021, the US FDA approved amivantamab-vmjw, marketed as RYBREVANT, for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations whose disease had progressed during or after platinum-based chemotherapy.
- Blinatumomab: Amgen
Blinatumomab, also known as AMG 103, is a bispecific T-cell engager that binds CD3 on T cells and CD19 on B-lineage cells. This mechanism promotes immune-mediated destruction of targeted malignant cells. It has received regulatory approval for specified forms of B-cell precursor acute lymphoblastic leukemia, with additional research exploring its potential in other hematological malignancies.
Explore the FDA-approved bispecific antibody drugs and review bispecific antibody market dynamics - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Bispecific Antibody Market Dynamics and Challenges
Advances in antibody engineering, rising R&D investment, and expanding clinical pipelines are shaping the competitive landscape. Companies such as Roche, Regeneron, Genmab, and Zymeworks are developing technologies intended to improve antibody stability, manufacturing, and pharmacokinetic properties. Platforms such as knob-into-hole, CrossMab, and DuoBody support the design of different bispecific formats.
Nevertheless, manufacturing remains complex and expensive, particularly for molecules requiring precise assembly of distinct antibody components. Safety considerations, including cytokine release syndrome, off-target activity, and immunogenicity, can also complicate development. Biomarker identification and patient stratification are therefore important for optimizing treatment selection and managing potential adverse events.
To learn more about bispecific antibody development and production, visit Bispecific Antibody Production - https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Key Developments in the Bispecific Antibody Domain
- In July 2025, Instil Bio announced US FDA clearance of an investigational new drug application for AXN-2510, a PD-L1 x VEGF bispecific antibody intended for a Phase I trial in relapsed or refractory solid tumors.
- In June 2025, Zai Lab reported preclinical findings for ZL-1503, an IL-13/IL-31R bispecific antibody designed to address inflammatory and itch-related pathways in atopic dermatitis. That month, BioNTech and Bristol Myers Squibb agreed to collaborate on the global development and commercialization of BNT327 across multiple solid tumors.
- In May 2025, Minghui Pharmaceutical announced the first-patient dosing in a Phase II study combining MHB039A, a PD-1 x VEGF bispecific antibody, with the TROP-2-targeting antibody-drug conjugate MHB036C in advanced NSCLC. Pfizer also entered an exclusive global licensing agreement, excluding China, with 3SBio for SSGJ-707, a PD-1 x VEGF bispecific antibody being evaluated in several cancer indications.
- In April 2025, the European Commission approved COLUMVI (glofitamab) with gemcitabine and oxaliplatin for specified adults with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem cell transplantation.
- Additional developments included a March 2025 patent grant in China for Ocean Biomedical's CHI3L1- and PD-1-targeting antibodies, first-patient dosing in a Phase I trial of CTIM-76 in March 2025, and preclinical presentation plans for Rondo Therapeutics' RNDO-564 in February 2025. In January 2025, Orion Corporation and Invenra announced a research collaboration using the B-Body platform, while Biocytogen and Acepodia announced a strategic collaboration involving dual-payload bispecific antibody-drug conjugates.
Scope of the Bispecific Antibody Competitive Landscape Report
The report provides global coverage of marketed therapies, pipeline candidates, and competitive developments. Key companies include Instil Bio, Akeso Biopharma, Janssen, Amgen, Roche, IGM Biosciences, MacroGenics, Regeneron Pharmaceuticals, Boehringer Ingelheim, ABL Bio, Compass Therapeutics, EpimAb Biotherapeutics, Affimed Therapeutics, Novo Nordisk, and others.
Featured candidates include AXN-2510, AK-104, amivantamab, blinatumomab, ivonescimab, zanidatamab, glofitamab, MGD024, KN-046, SI-B001, REGN-5458, CTX-8371, MCLA-129, AFM13, and Mim8.
Conclusion
The bispecific antibody landscape continues to evolve as researchers explore dual-targeting approaches across oncology, autoimmune diseases, and other therapeutic areas. With more than 180 companies investigating over 250 candidates, the pipeline offers substantial opportunities for innovation while presenting challenges involving manufacturing, safety, and clinical validation. Continued research, regulatory progress, and strategic partnerships will influence the future development and commercial potential of these therapies.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Abhishek kumar